8-K: Assembly Bio's HSV Inhibitors Exceed Efficacy Targets

Assembly Biosciences reports positive interim Phase 1b results for ABI-1179 and ABI-5366, showing significant reductions in viral shedding and genital lesions for recurrent genital herpes.

Summary

• Assembly Biosciences announced positive interim results from Phase 1b clinical studies for two investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-1179 and ABI-5366, for recurrent genital herpes.
• ABI-1179 (50 mg weekly oral dose) demonstrated highly potent antiviral activity with a 98% reduction in HSV-2 shedding rate compared to placebo (p<0.01), exceeding the company's target of 80%-85%.
• ABI-1179 also showed a 91% reduction in virologically confirmed genital lesion rate (p<0.01) and over 99% reduction in high viral load samples.
• ABI-5366 (monthly oral dosing cohort) showed potent antiviral activity with a 76% reduction in HSV-2 shedding rate (p<0.01), an 88% reduction in virologically confirmed genital lesion rate (p<0.01), and an 81% reduction in high viral load samples (p<0.01).
• Previously reported weekly dosing of ABI-5366 (350 mg) showed even higher efficacy: 94% reduction in HSV-2 shedding rate (p<0.01) and 97% reduction in virologically confirmed genital lesion rate (p<0.05).
• Both candidates were observed to be well-tolerated across all evaluated oral dosing regimens, with pharmacokinetic profiles supporting their respective dosing schedules.
• The company is progressing Phase 2 enabling activities for ABI-1179 and plans to initiate longer-duration Phase 2 clinical studies for once-weekly ABI-5366 regimens in mid-2026.

Sentiment

Score: 9

Explanation: The interim Phase 1b results for both ABI-1179 and ABI-5366 are overwhelmingly positive, with ABI-1179 exceeding efficacy targets and both candidates demonstrating good tolerability. The progress towards Phase 2 and the potential for long-acting, superior treatments for recurrent genital herpes are highly favorable. The only minor caveat is the optimization needed for ABI-5366 monthly dosing, but weekly dosing remains very strong.

Positives

• ABI-1179 (50 mg weekly) achieved a 98% reduction in HSV-2 shedding rate, significantly exceeding the company's target of 80%-85%.
• ABI-1179 (50 mg weekly) demonstrated a 91% reduction in virologically confirmed genital lesion rate and over 99% reduction in high viral load samples.
• ABI-5366 (monthly dosing) showed potent antiviral activity with a 76% reduction in HSV-2 shedding rate and an 88% reduction in virologically confirmed genital lesion rate.
• Both ABI-1179 and ABI-5366 were well-tolerated at all tested oral doses, with safety profiles similar to placebo for most adverse events.
• The pharmacokinetic profiles of both candidates support their respective once-weekly and potentially once-monthly dosing regimens.
• The company is advancing both candidates towards Phase 2 clinical evaluation, with ABI-5366 Phase 2 studies planned for mid-2026.
• The helicase-primase inhibition mechanism is clinically validated and shows potential for superior efficacy compared to current standard of care.

Negatives

• The monthly oral dosing of ABI-5366, while encouraging, showed a lower reduction in HSV-2 shedding rate (76%) compared to the weekly 350 mg dose (94%).
• For ABI-5366 monthly dosing, 89% of positive swabs were collected in the last two weeks of the evaluation period when drug levels were declining, suggesting potential for optimization of exposure.
• One participant in the ABI-1179 20 mg/placebo cohort reported a Grade 3 migraine, though overall treatment-emergent adverse events were similar to placebo.
• One participant in the ABI-5366 study had a Grade 3 hypertriglyceridemia, which was later deemed unrelated to treatment and pre-existing.

Risks

• Ability to realize the potential benefits of the collaboration with Gilead, including financial aspects and equity investments.
• Ability to initiate and complete clinical studies in anticipated timeframes or at all.
• Safety and efficacy data from clinical or nonclinical studies may not warrant further development of product candidates.
• Clinical and nonclinical data may not differentiate product candidates from other companies' candidates.
• Ability to maintain financial resources and secure additional funding necessary for research, clinical studies, and business operations.
• Potential effects of changes in government regulation.
• Results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of clinical study outcomes.

Future Outlook

The company plans to pursue optimization efforts for ABI-5366 monthly oral dosing and initiate longer-duration Phase 2 clinical studies for once-weekly ABI-5366 regimens in mid-2026. In parallel, it is evaluating the potential to advance ABI-1179 into Phase 2 clinical evaluation and is progressing Phase 2 enabling activities for this candidate. Gilead Sciences has an option to license the helicase-primase inhibitor program for further development and commercialization after the Phase 1b studies conclude.

Management Comments

• "As we saw with ABI-5366, weekly oral dosing of ABI-1179 outperformed our expectations for antiviral efficacy and improvement in clinical outcomes, and we are thrilled with these Phase 1b findings for both highly promising candidates." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.
• "The ABI-5366 monthly oral dosing results are also encouraging and show significant reductions in viral shedding and virologically confirmed genital lesion rate, supporting the continued optimization of exposure to evaluate its potential for monthly oral dosing." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.
• "We expect to pursue such optimization efforts in parallel with moving once-weekly ABI-5366 regimens into longer-duration Phase 2 clinical studies, which we plan to initiate in mid-2026." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.
• "In parallel, we are evaluating the potential to also advance ABI-1179 into Phase 2 clinical evaluation and are progressing Phase 2 enabling activities for this candidate." Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.

Industry Context

The announcement highlights significant progress in developing new treatments for recurrent genital herpes, a chronic viral infection affecting over four million people in the US and major European countries. The current standard of care, nucleoside analogs, is only partially effective and no new drugs have been approved in over 25 years. Assembly Bio's helicase-primase inhibitors target a conserved viral enzyme complex, offering a potentially superior efficacy mechanism compared to existing treatments, addressing a substantial unmet medical need in the infectious disease market.

Comparison to Industry Standards

• Current standard of care for recurrent genital herpes involves nucleoside analogs, which are only partially effective in preventing recurrences and reducing transmission.
• Assembly Bio's helicase-primase inhibitors, ABI-1179 and ABI-5366, target an essential viral enzyme complex (helicase-primase) that has no host equivalent, a mechanism clinically validated to show potential for superior efficacy.
• ABI-1179 (50 mg weekly) achieved a 98% reduction in HSV-2 shedding rate, significantly outperforming the 80%-85% target, suggesting a higher efficacy profile than current treatments.
• ABI-5366 (350 mg weekly) showed a 94% reduction in HSV-2 shedding rate and 97% reduction in virologically confirmed genital lesion rate, also indicating strong performance relative to existing options.
• The long-acting nature and potential for once-weekly or once-monthly dosing for these candidates represent a significant improvement in convenience and adherence compared to daily or intermittent dosing of current nucleoside analogs.

Related Party Transactions

• ABI-1179 was contributed by Gilead Sciences under the collaboration agreement between Assembly Bio and Gilead.
• Gilead Sciences has the right to opt in to an exclusive license for further development and commercialization of the helicase-primase inhibitor program after Phase 1b studies.

Stakeholder Impact

• Shareholders: Highly positive clinical trial results, especially for ABI-1179 exceeding efficacy targets, could lead to increased investor confidence and potential share price appreciation. The advancement to Phase 2 and the Gilead collaboration option are also positive indicators.
• Patients (Recurrent Genital Herpes): The development of long-acting, highly effective helicase-primase inhibitors offers the potential for significantly improved treatment options, better quality of life, and reduced transmission risk compared to current therapies.
• Employees: Positive clinical progress and advancement to later-stage trials can boost morale and provide job security, especially in R&D.
• Gilead Sciences: As a collaborator and potential licensee, Gilead benefits from the successful progression of these candidates, particularly ABI-1179 which they contributed. The positive data strengthens their option to license.

Next Steps

• Completion of the ongoing Phase 1b study for ABI-1179, including a third and potentially a fourth cohort.
• Progressing Phase 2 enabling activities for ABI-1179.
• Optimization efforts for ABI-5366 monthly oral dosing.
• Initiation of longer-duration Phase 2 clinical studies for once-weekly ABI-5366 regimens in mid-2026.
• Delivery of an option data package to Gilead Sciences following the end of the Phase 1b studies for Gilead to review its option to license the program.
• Company to hold a conference call on December 8, 2025, at 6 p.m. ET.

Key Dates

Recommendation

The clinical trial results are exceptionally strong, particularly for ABI-1179, which significantly exceeded efficacy targets. Both candidates demonstrated excellent tolerability and have pharmacokinetic profiles supporting convenient dosing. The unmet medical need for recurrent genital herpes is substantial, and these novel helicase-primase inhibitors show potential for superior efficacy over the current standard of care. The progression to Phase 2 and the existing collaboration with Gilead Sciences, including their option to license, de-risk future development and commercialization. These factors collectively point to a highly favorable outlook for the company's pipeline and stock performance.

Keywords

herpes simplex virus, HSV-2, genital herpes, helicase-primase inhibitor, ABI-1179, ABI-5366, Phase 1b clinical trial, antiviral, viral shedding, genital lesions, biotechnology, drug development, Gilead Sciences, clinical results